

**Supplementary Table 1. Data Characteristics**

Cohort	Population Group	N	EDS Presence		Females	Age	BMI	AHI
			N (%)	N (%)	N (%)	Mean (SD)	Mean, (SD)	Mean (SD)
<b>Whole Genome Sequencing Data</b>								
ARIC	EUR	1083	311 (14.4%)	575 (8.77%)	62.19 (5.70)	28.79 (5.07)	13.65 (14.20)	
HCHS/SOL	HIS	5927	902 (41.7%)	3426 (52.27%)	46.73 (13.87)	30.06 (6.36)	6.76 (12.72)	
CFS	EUR	481	138 (6.4%)	242 (3.69%)	43.60 (19.69)	30.86 (8.87)	17.96 (24.76)	
	AFR	505	184 (8.5%)	285 (4.35%)	38.96 (19.08)	32.38 (9.46)	19.11 (26.80)	
FHS	EUR	464	86 (4.0%)	231 (3.52%)	60.01 (8.50)	28.49 (5.13)	12.36 (13.31)	
MESA	AFR	488	88 (4.1%)	263 (4.01%)	68.67 (9.08)	30.28 (5.68)	19.48 (19.70)	
	EUR	694	77 (3.6%)	370 (5.65%)	68.53 (9.08)	27.89 (5.09)	18.39 (17.80)	
	HIS	454	57 (2.6%)	240 (3.66%)	68.29 (9.21)	30.08 (5.46)	21.73 (18.51)	
	EAS	223	27 (1.2%)	113 (1.72%)	67.74 (9.06)	24.25 (3.29)	20.54 (18.70)	
CHS	EUR	540	109 (5.0%)	318 (4.85%)	77.72 (4.24)	27.30 (4.43)	15.36 (15.61)	
	AFR	193	59 (2.7%)	120 (1.83%)	75.69 (4.67)	28.64 (4.93)	15.26 (15.02)	
JHS	AFR	567	126 (5.8%)	371 (5.66%)	63.45 (10.88)	31.87 (6.89)	15.69 (15.93)	
<b>TOTAL</b>		<b>11619</b>	<b>2164</b>	<b>6554</b>				
<b>Imputed Genotype Data</b>								
ARIC	EUR	457	133 (7.30%)	229 (6.28%)	62.90 (5.68)	28.97 (5.14)	14.76 (16.84)	
CFS	AFR	72	16 (0.88%)	39 (1.07%)	26.19 (18.18)	26.79 (9.61)	7.96 (15.28)	
	EUR	103	19 (1.04%)	55 (1.51%)	38.11 (17.83)	29.47 (7.13)	13.91 (21.06)	
CHS	EUR	216	51 (2.80%)	140 (3.84%)	77.74 (4.41)	26.84 (4.40)	15.08 (14.00)	
	AFR	8	4 (0.22%)	1 (0.03%)	75.50 (5.37)	28.10 (2.89)	23.16 (14.23)	
FHS	EUR	139	27 (1.48%)	69 (1.89%)	56.55 (9.74)	28.54 (4.75)	13.90 (16.19)	
WASHS	EUR	1493	648 (35.5%)	607 (16.66%)	52.30 (13.77)	31.86 (7.89)	14.43 (18.68)	
MrOS	EUR	2209	279 (15.3%)	0 (0.00%)	76.68 (5.67)	27.22 (3.74)	17.31 (15.49)	
HCHS/SOL	HIS	4207	646 (35.4%)	2504 (68.72%)	45.32 (13.69)	29.33 (5.35)	5.91 (11.37)	
<b>TOTAL</b>		<b>8904</b>	<b>1823</b>	<b>3644</b>				

**Supplementary Table 2. Extended Gene Loci Identified by FUMA SNP2GENE – Interaction Effect, WGS Discovery Analysis**

<b>Gene</b>	<b>eQTL</b>	<b>eQTL Association Tissues</b>	<b>Position</b>	<b>Chromatin Interaction</b>	<b>Chromatin Interaction Tissues</b>	<b>Lead Variant</b>
<b>NAF1</b>	0		0	Yes	Mesenchymal_Stem_Cell	rs13118183
<b>NPY1R</b>	0		0	Yes	Mesenchymal_Stem_Cell	rs13118183
<b>NPY5R</b>	1	CMC_SVA_cis	0	Yes	Mesenchymal_Stem_Cell	rs13118183
<b>TKTL2</b>	0		0	Yes	Mesendoderm:hESC	rs13118183
					Dorsolateral_Prefrontal_Cortex, Left_Ventricle, Liver, IMR90,	
<b>MARCHF1</b>	21	CMC_NoSVA_cis, GTEx/v8/Adipose_Visceral_ Omentum	218	Yes	Mesenchymal_Stem_Cell, Mesendoderm, Neural_Progenitor_Cell, Trophoblast- like_Cell:hESC	rs13118183
<b>FAM218A</b>	0		0	Yes	Mesendoderm, hESC	rs13118183
<b>TRIM60</b>	0		0	Yes	Promoter_anchored_loops	rs13118183
<b>UPF2</b>	0		0	Yes	Mesenchymal_Stem_Cell	rs281851
<b>DHTKD1</b>	0		0	Yes	Mesenchymal_Stem_Cell	rs281851
<b>SEC61A2</b>	0		0	Yes	Mesenchymal_Stem_Cell	rs281851
					Left_Ventricle, Liver, GM12878, IMR90, Mesenchymal_Stem_Cell,	
<b>NUDT5</b>	0		0	Yes	Mesendoderm, Trophoblast- like_Cell, hESC	rs281851
					Left_Ventricle, Liver, GM12878, IMR90, Mesenchymal_Stem_Cell,	
<b>CDC123</b>	0		0	Yes	Mesendoderm, Trophoblast- like_Cell, hESC	rs281851
					IMR90, Mesenchymal_Stem_Cell,	
<b>CAMK1D</b>	0		0	Yes	Mesendoderm, Trophoblast- like_Cell, hESC	rs281851
		PsychENCODE_eQTLs, CMC_SVA_cis, GTEx/v8/Adipose_Subcutan- eous,				
		GTEx/v8/Adipose_Visceral_- Omentum,				
<b>CCDC3</b>	65	GTEx/v8/Artery_Aorta, GTEx/v8/Artery_Tibial, GTEx/v8/Colon_Sigmoid, GTEx/v8/Heart_Left_Ventric- le, GTEx/v8/Lung, GTEx/v8/Nerve_Tibial, GTEx/v8/Cells_Cultured_fib- roblasts	77	Yes	IMR90, Mesenchymal_Stem_Cell, Mesendoderm, hESC	rs281851
<b>OPTN</b>	0	2	0	Yes	IMR90, Mesenchymal_Stem_Cell, Mesendoderm, hESC	rs281851
<b>PHYH</b>	1	eQTLGen_cis_eQTLs	0	No		rs281851

**Supplementary Table 3. Variation in Number of Variants Mapped to Gene Sets – Rare Variant Set Analysis**

<b>Gene</b>	<b>Sex</b>	<b># Variants in WGS</b>	<b># Variants in Imputed</b>
<i>SCUBE2</i>	Combined	25	3
<i>TMEM26</i>	Male	2	0
<i>CPSF4L</i>	Male	5	1

Supplementary Table 4. Common Variant Analysis WGS Additional Significant Loci – Main Genetic Effect

rsID	Sex	Chr:Pos (b38)	Eff/Alt	EAF	Gene Locus (FUMA SNP2GENE)	N	MAIN GENETIC EFFECT		INTERACTION EFFECT		JOINT EFFECT
							Beta (SE)	P-Value	Beta (SE)	P-Value	
rs35370454*	Combined	7:11242 5915	C/T	0.99	<i>IMMP2L,</i> <i>LRRN3,</i> <i>DOCK4,</i> <i>ZNF277,</i> <b><i>IFRD1,</i></b> <i>LSMEM1,</i> <i>TMEM168,</i> <i>C7orf60,</i> <i>GPR85,</i> <i>LINC00998,</i> <i>TSRM</i>	11615	0.024 (0.004)	<b>1.32E-08</b>	-0.028 (0.012)	2.35E-02	9.18E-08
rs13433190*	Female	20:3751 618	G/T	0.93	<i>TMEM239,</i> <i>DDRGK1,</i> <i>GFRA4,</i> <i>ADAM33,</i> <i>SIGLEC1,</i> <b><i>HSPA12B,</i></b> <i>C20orf27,</i> <i>SPEF1,</i> <i>CENPB,</i> <i>CDC25B,</i> <i>MAVS, RP11-</i> <i>352D3.2</i>	6546	0.018 (0.003)	<b>6.07E-09</b>	-0.012 (0.009)	1.75E-01	3.48E-08

\* rs35370454 and rs13433190 were not present in imputed genotype data.

**Supplementary Table 5. Rare Variant WGS Set-Based Analysis Additional Significant Results – Main Genetic Effect**

					<i>MAIN GENETIC EFFECT</i>	<i>INTERACTION EFFECT</i>	<i>JOINT EFFECT</i>
Gene	Chr:Position (b38)	Sex	Dataset	# of Variants	P-Value	P-Value	P-Value
<b>HBB*</b>	11:5,225,464- 5,229,395	Female	WGS	1	<b>2.75E-06</b>	3.27E-02	9.89E-06
<b>KRR1*</b>	12:75,490,86 3-75,511,636 5:137,887,96	Female	WGS	2	<b>3.06E-06</b>	6.80E-01	2.74E-04
<b>PKD2L2</b>	8- 137,942,747	Male	WGS	9	1.19E-05	3.77E-03	<b>1.42E-06</b>
			Imputed	2	7.14E-01	8.24E-01	9.00E-01
<b>UBOX5</b>	20:3,107,573- 3,160,196	Male	WGS	2	<b>9.70E-09</b>	1.83E-02	<b>2.07E-08</b>
			Imputed	1	7.82E-01	7.58E-01	9.03E-01

\*Variant sets mapped to HBB and KRR1 were not present in imputed genotype data

**Supplementary Table 6. Rare Variant Set-Based Meta-Analysis Additional Significant Loci – Main Genetic Effect**

			MAIN GENETIC EFFECT	INTERACTION EFFECT	JOINT EFFECT
Gene	Chr:Pos (b38)	Sex	Number of Variants	P-Value	P-Value
<i>UQCC3</i>	11:62,670,273- 62,673,686	Combined	3	<b>3.51E-07</b>	1.39E-02
<i>C6orf52</i>	6:10,671,418- 10,694,797	Female	2	2.00E-05	4.41E-04
<i>TCF4</i>	18:55,222,185- 55,664,787	Female	2	<b>4.23E-07</b>	3.78E-02
<i>ZNF383</i>	19:37,217,926- 37,248,740	Female	2	2.29E-04	2.59E-04
<i>SYS1</i>	20:45,361,937- 45,376,798	Female	2	<b>1.27E-06</b>	1.01E-02
<i>OSE1R1</i>	20:44,195,939- 44,210,771	Female	2	<b>1.46E-06</b>	2.94E-01
<i>PAPOLG</i>	2:60,756,253- 60,802,086	Male	3	<b>1.70E-06</b>	8.00E-01
<i>TBX20</i>	7:35,202,430- 35,254,100	Male	2	3.27E-05	2.60E-04
<i>ACAT1</i>	11:108,116,695- 108,147,603	Male	1	<b>9.84E-07</b>	1.31E-04
<i>TGDS</i>	13:94,574,054- 94,596,242	Male	2	<b>4.72E-09</b>	3.33E-02
<i>CHAMP1</i>	13:114,314,482- 114,337,626	Male	3	<b>5.98E-09</b>	1.87E-02
<i>RPS15A</i>	16:18,781,295- 18,790,383	Male	2	<b>7.75E-09</b>	2.59E-02
<i>ZNF112</i>	19:44,326,555- 44,367,217	Male	6	<b>8.76E-07</b>	8.93E-01
<i>PIM3</i>	22:49,960,768- 49,964,072	Male	2	<b>7.62E-09</b>	6.82E-05

**Supplementary Table 7. Assessing Whether Genomic Loci for OSA Are Previously Unreported**

Variant or Gene	Unreported	GWAS Catalog	PheWeb	Prior OSA GWAS Studies **
<i>rs13118183</i>	*		-	-
<i>rs281851</i>	*		-	-
<i>SCUBE2</i>		Total protein levels x insomnia interaction; Personality traits or cognitive traits (multivariate analysis); Waist-hip ratio	-	Min SpO2 [S4];
<i>TMEM26</i>	*	Total PHF-tau (SNP x SNP interaction); Cognitive ability, years of educational attainment or schizophrenia (pleiotropy); Diffuse plaques (SNP x SNP interaction); Diastolic BP; Systolic BP; PR Interval ; BMI; Adult body size; Body mass index (MTAG)	Hypertension	-
<i>CPSF4L</i>	*	Red cell distribution width	-	-
<i>UBLCP1</i>			-	AHI 3% [S4]; Avg Desaturation 0% [S4, S5];
<i>MED31</i>	*	Systolic BP; Waist circumference adjusted for body mass index	-	-
<i>RAP1GAP</i>	*	Immature fraction of reticulocytes; High light scatter reticulocyte percentage of red cells; High light scatter reticulocyte count; Mean reticulocyte volume; Abdominal aortic calcification levels;	-	-
<i>CPNE5</i>		Heart rate variability traits (SDNN); Heart rate variability traits (RMSSD); Heart rate variability (standard deviation of normal-to-normal intervals); Heart rate variability (corrected standard deviation of normal-to-normal intervals); Heart rate variability (corrected root mean square of successive differences); Heart rate variability (root mean square of successive differences); Resting heart rate; Heart rate variability traits (pvRSA/HF); Pulse Pressure; Heart rate response to exercise	-	Min SpO2 [S4];

<b>MYMX</b>		Mean spheric corpuscular volume; Diastolic BP; Mean reticulocyte volume	-	Avg SpO2 [S4]; Per90 [S4, S5]
<b>YY1</b>	*	Caudate nucleus volume; Dementia; Pulse Pressure;	Atherosclerosis of aorta	-
<b>ZNF773</b>			-	Min SpO2 [S4];
<b>YBEY</b>			-	Avg Desaturation 0% [S4]
<b>IQCB1</b>		Multiple sclerosis; Mean corpuscular volume; Hemoglobin levels	-	Avg SpO2 [S4, S5]; Min SpO2 [S4, S5]; Per90 [S4, S5];
<b>PI4K2B</b>	*		-	-
<b>CORO1A</b>		Cortical thickness; Brain morphology (MOSTest); Multiple sclerosis; BMI; Whole body fat mass (UKB data field 23100)	-	AHI 3% [S4];

\*\*Four prior large-scale OSA-related GWAS studies were assessed: Sofer et al 2023 [PMID: 36989840; Table 1, Supplementary Tables S2-S3,S6, S7-S8 (FDR-BH<=0.05), S9-S17], Cade et al 2021 [PMID: 34446064; Tables 3-5, Supplementary Tables S4-S5 [P<0.01]], Strausz et al 2021 [PMID: 33243845; Table 2, Figures S5,S7], and Xu et al 2022 [PMID: 35819321; Table 1, Table 2, Supplementary Tables E3-E5]. Amongst these studies overlapped genes was identified

Supplementary Table 8. Stratified Analysis According to Exposure Status – Common Variants – WGS Data

rsID	Exposure Status	Sex	Chr:Position (b38)	Effect		Gene	N	Beta (SE)	P	Direction of Effect
				Allele / Alternative Allele	Effect Allele Frequency					
<b>rs13118183</b>	EDS	Combined	4:164200775	A/G	0.937	<i>MARCHF1</i>	2163	0.025 (0.006)	3.30E-05	+
<b>rs13118183</b>	EDS	Female	4:164200775	A/G	0.933	<i>MARCHF1</i>	1137	0.020 (0.010)	4.60E-02	+
<b>rs13118183</b>	EDS	Male	4:164200775	A/G	0.942	<i>MARCHF1</i>	1026	0.026 (0.008)	6.00E-04	+
<b>rs13118183</b>	No EDS	Combined	4:164200775	A/G	0.939	<i>MARCHF1</i>	9451	-0.009 (0.002)	5.40E-05	-
<b>rs13118183</b>	No EDS	Female	4:164200775	A/G	0.939	<i>MARCHF1</i>	5413	-0.012 (0.004)	1.40E-03	-
<b>rs13118183</b>	No EDS	Male	4:164200775	A/G	0.939	<i>MARCHF1</i>	4038	-0.009 (0.003)	4.30E-03	-
<b>rs281851</b>	EDS	Combined	10:12924495	A/C	0.605	<i>CCDC3</i>	2163	0.018 (0.003)	<b>4.46E-09</b>	+
<b>rs281851</b>	EDS	Female	10:12924495	A/C	0.608	<i>CCDC3</i>	1137	0.019 (0.005)	1.94E-04	+
<b>rs281851</b>	EDS	Male	10:12924495	A/C	0.602	<i>CCDC3</i>	1026	0.016 (0.004)	6.00E-06	+
<b>rs281851</b>	No EDS	Combined	10:12924495	A/C	0.588	<i>CCDC3</i>	9452	-0.001 (0.001)	3.73E-01	-
<b>rs281851</b>	No EDS	Female	10:12924495	A/C	0.59	<i>CCDC3</i>	5414	-0.001 (0.002)	6.54E-01	-
<b>rs281851</b>	No EDS	Male	10:12924495	A/C	0.59	<i>CCDC3</i>	4038	-0.001 (0.001)	3.60E-01	-

**Supplementary Table 9. Stratified Meta-Analysis According to Exposure Status – Rare Variants**

Gene	Exposure Status	Sex	Number of Variants	P-Value
<b><i>UBLCP1</i></b>	EDS	Combined	2	3.39E-02
<b><i>UBLCP1</i></b>	No EDS	Combined	15	6.53E-01
<b><i>SCUBE2</i></b>	EDS	Combined	50	9.60E-01
<b><i>SCUBE2</i></b>	No EDS	Combined	99	5.90E-01
<b><i>MED31</i></b>	EDS	Combined	1	5.56E-01
<b><i>MED31</i></b>	No EDS	Combined	6	8.09E-01
<b><i>RAP1GAP</i></b>	EDS	Female	2	8.62E-01
<b><i>RAP1GAP</i></b>	No EDS	Female	2	6.43E-01
<b><i>CPNE5</i></b>	EDS	Female	11	3.11E-02
<b><i>CPNE5</i></b>	No EDS	Female	33	7.58E-01
<b><i>MYMX</i></b>	EDS	Female	2	2.02E-02
<b><i>MYMX</i></b>	No EDS	Female	2	3.26E-02
<b><i>YY1</i></b>	EDS	Female	*	*
<b><i>YY1</i></b>	No EDS	Female	2	9.63E-01
<b><i>ZNF773</i></b>	EDS	Female	8	2.26E-01
<b><i>ZNF773</i></b>	No EDS	Female	30	3.17E-01
<b><i>YBEY</i></b>	EDS	Female	3	6.99E-01
<b><i>YBEY</i></b>	No EDS	Female	8	7.35E-01
<b><i>IQCB1</i></b>	EDS	Male	10	7.59E-01
<b><i>IQCB1</i></b>	No EDS	Male	32	4.72E-01
<b><i>P14K2B</i></b>	EDS	Male	9	4.05E-01
<b><i>P14K2B</i></b>	No EDS	Male	15	5.36E-01
<b><i>TMEM26</i></b>	EDS	Male	5	1.06E-02
<b><i>TMEM26</i></b>	No EDS	Male	14	2.44E-01
<b><i>CORO1A</i></b>	EDS	Male	4	4.70E-01
<b><i>CORO1A</i></b>	No EDS	Male	13	1.98E-01
<b><i>CPSF4L</i></b>	EDS	Male	9	4.96E-01
<b><i>CPSF4L</i></b>	No EDS	Male	14	2.45E-01

\* Denotes this variant set was not available in this subset of samples.

**Supplementary Table 10. MAGMA Tissue-Enrichment Analysis Significant Results**

Sex	Tissue	Beta	Standard Error	P-Value
Female	Breast Mammary Tissue	0.069494	0.01739	<b>3.24E-05</b>
Female	Tibial Nerve	0.049348	0.013949	<b>2.03E-04</b>

\*Bonferroni Threshold: p<9.3e-04

**Supplementary Table 11. MAGMA Gene-Level Analysis Significant Results\***

<b>Gene</b>	<b>Position</b>	<b>Sex</b>	<b>Number of Variants</b>	<b>N</b>	<b>Z-Statistic</b>	<b>P-Value</b>
<b><i>NOP53</i></b>	19:47,745,546-47,757,058	Combined	3	11615	4.7344	<b>1.10E-06</b>
<b><i>EYA2</i></b>	20:46,894,624-47,188,844	Combined	18	11614	4.6463	<b>1.69E-06</b>
<b><i>ZNF563</i></b>	19:12,317,477-12,333,720	Combined	4	11614	4.5472	<b>2.72E-06</b>
<b><i>WDR19</i></b>	4:39,182,504-39,285,810	Female	9	6551	4.6988	<b>1.31E-06</b>

\*Bonferroni Threshold: p<4.3e-06

Supplementary Table 12. Open Targets Platform Identified Mouse Phenotypes

mouseGene	phenotype	category
<i>Marchf1</i>	decreased interleukin-12 secretion	immune system phenotype
<i>Marchf1</i>	abnormal B cell physiology	hematopoietic system phenotype,immune system phenotype
<i>Marchf1</i>	decreased tumor necrosis factor secretion	immune system phenotype
<i>Marchf1</i>	decreased regulatory T cell number	hematopoietic system phenotype,immune system phenotype
<i>Marchf1</i>	abnormal T cell differentiation	hematopoietic system phenotype,immune system phenotype
<i>Marchf1</i>	abnormal dendritic cell antigen presentation	immune system phenotype
<i>Marchf1</i>	abnormal dendritic cell morphology	hematopoietic system phenotype,immune system phenotype
<i>Marchf1</i>	abnormal level of surface class II molecules	immune system phenotype
<i>Ccdc3</i>	increased circulating glucose level	homeostasis/metabolism phenotype
<i>Ccdc3</i>	abnormal fat pad morphology	adipose tissue phenotype
<i>Ccdc3</i>	weight loss	growth/size/body region phenotype
<i>Ccdc3</i>	decreased liver weight	liver/biliary system phenotype
<i>Ccdc3</i>	increased insulin sensitivity	homeostasis/metabolism phenotype
<i>Ccdc3</i>	decreased susceptibility to age-related hepatic steatosis	liver/biliary system phenotype
<i>Ccdc3</i>	abnormal glucose homeostasis	homeostasis/metabolism phenotype
<i>Ccdc3</i>	decreased white fat cell size	adipose tissue phenotype
<i>Ccdc3</i>	decreased liver triglyceride level	homeostasis/metabolism phenotype,liver/biliary system phenotype
<i>Ccdc3</i>	decreased circulating leptin level	homeostasis/metabolism phenotype
<i>Ccdc3</i>	decreased subcutaneous adipose tissue amount	integument phenotype,adipose tissue phenotype
<i>Ublcp1</i>	tremors	behavior/neurological phenotype
<i>Med31</i>	decreased fibroblast proliferation	cellular phenotype
<i>Med31</i>	abnormal cartilage development	skeleton phenotype
<i>Med31</i>	pallor	integument phenotype
<i>Med31</i>	edema	homeostasis/metabolism phenotype
<i>Med31</i>	embryonic growth retardation	embryo phenotype,growth/size/body region phenotype
<i>Med31</i>	lethality throughout fetal growth and development, complete penetrance	mortality/aging
<i>Med31</i>	decreased embryo size	embryo phenotype,growth/size/body region phenotype
<i>Med31</i>	abnormal embryonic growth/weight/body size	growth/size/body region phenotype
<i>Med31</i>	open neural tube	embryo phenotype,nervous system phenotype
<i>Med31</i>	decreased fetal size	growth/size/body region phenotype
<i>Med31</i>	small thoracic cage	skeleton phenotype
<i>Med31</i>	spina bifida	embryo phenotype,nervous system phenotype

<i>Med31</i>	abnormal skeleton morphology	skeleton phenotype
<i>Med31</i>	decreased cell proliferation	cellular phenotype
<i>Med31</i>	abnormal limb development	limbs/digits/tail phenotype
<i>Med31</i>	small cranium	craniofacial phenotype,skeleton phenotype
<i>Med31</i>	decreased bone ossification	skeleton phenotype
<i>Scube2</i>	decreased bone trabecula number	skeleton phenotype
<i>Scube2</i>	abnormal skeleton development	skeleton phenotype
<i>Scube2</i>	abnormal bone ossification	skeleton phenotype
<i>Scube2</i>	decreased trabecular bone volume	skeleton phenotype
<i>Scube2</i>	abnormal trabecular bone morphology	skeleton phenotype
<i>Scube2</i>	decreased volumetric bone mineral density	skeleton phenotype
<i>Scube2</i>	short femur	limbs/digits/tail phenotype,skeleton phenotype
<i>Scube2</i>	abnormal long bone epiphyseal plate proliferative zone	skeleton phenotype
<i>Scube2</i>	abnormal endochondral bone ossification	skeleton phenotype
<i>Scube2</i>	decreased osteoblast cell number	skeleton phenotype
<i>Scube2</i>	decreased compact bone thickness	skeleton phenotype
<i>Scube2</i>	decreased chondrocyte proliferation	cellular phenotype,skeleton phenotype
<i>Scube2</i>	decreased body size	growth/size/body region phenotype
<i>Scube2</i>	decreased body weight	growth/size/body region phenotype
<i>Scube2</i>	abnormal chondrocyte differentiation	skeleton phenotype
<i>Scube2</i>	decreased trabecular bone thickness	skeleton phenotype
<i>Scube2</i>	abnormal long bone hypertrophic chondrocyte zone	skeleton phenotype
<i>Scube2</i>	decreased body height	growth/size/body region phenotype
<i>Scube2</i>	short tibia	limbs/digits/tail phenotype,skeleton phenotype
<i>Scube2</i>	decreased body length	growth/size/body region phenotype
<i>Eya2</i>	increased or absent threshold for auditory brainstem response	hearing/vestibular/ear phenotype
<i>Eya2</i>	enlarged spleen	hematopoietic system phenotype,immune system phenotype,growth/size/body region phenotype
<i>Eya2</i>	enlarged lymph nodes	immune system phenotype
<i>Eya2</i>	abnormal spleen morphology	hematopoietic system phenotype,immune system phenotype
<i>Eya2</i>	abnormal lymph node morphology	immune system phenotype
<i>Eya2</i>	small thymus	hematopoietic system phenotype,immune system phenotype,endocrine/exocrine gland phenotype
<i>Eya2</i>	impaired hearing	hearing/vestibular/ear phenotype
<i>Eya2</i>	abnormal pinna reflex	behavior/neurological phenotype
<i>Eya2</i>	small spleen	hematopoietic system phenotype,immune system phenotype
<i>Rap1gap</i>	increased red blood cell distribution width	hematopoietic system phenotype

<i>Rap1gap</i>	increased circulating amylase level	homeostasis/metabolism phenotype
<i>Rap1gap</i>	decreased lymphocyte cell number	hematopoietic system phenotype,immune system phenotype
<i>Rap1gap</i>	increased neutrophil cell number	hematopoietic system phenotype,immune system phenotype
<i>Rap1gap</i>	increased eosinophil cell number	hematopoietic system phenotype,immune system phenotype
<i>Cpne5</i>	abnormal spleen morphology	hematopoietic system phenotype,immune system phenotype
<i>Cpne5</i>	decreased anxiety-related response	behavior/neurological phenotype
<i>Mymx</i>	primary atelectasis	respiratory system phenotype
<i>Mymx</i>	abnormal muscle morphology	muscle phenotype
<i>Mymx</i>	abnormal limb morphology	limbs/digits/tail phenotype
<i>Mymx</i>	abnormal myoblast fusion	muscle phenotype,cellular phenotype
<i>Mymx</i>	muscle weakness	muscle phenotype
<i>Mymx</i>	cyanosis	homeostasis/metabolism phenotype
<i>Mymx</i>	abnormal limb muscle morphology	muscle phenotype,limbs/digits/tail phenotype
<i>Mymx</i>	abnormal spine curvature	skeleton phenotype
<i>Mymx</i>	abnormal intercostal muscle morphology	muscle phenotype
<i>Mymx</i>	nuchal edema	homeostasis/metabolism phenotype,integument phenotype,growth/size/body region phenotype
<i>Mymx</i>	abnormal skeletal muscle morphology	muscle phenotype
<i>Mymx</i>	decreased fetal weight	growth/size/body region phenotype
<i>Mymx</i>	neonatal lethality, complete penetrance	mortality/aging
<i>Yy1</i>	no abnormal phenotype detected	normal phenotype
<i>Yy1</i>	cyanosis	homeostasis/metabolism phenotype
<i>Yy1</i>	decreased cell proliferation	cellular phenotype
<i>Yy1</i>	prenatal lethality, incomplete penetrance	mortality/aging
<i>Yy1</i>	respiratory failure	respiratory system phenotype
<i>Yy1</i>	exencephaly	nervous system phenotype
<i>Yy1</i>	decreased birth body size	growth/size/body region phenotype
<i>Yy1</i>	decreased embryo size	embryo phenotype,growth/size/body region phenotype
<i>Yy1</i>	lethality throughout fetal growth and development, incomplete penetrance	mortality/aging
<i>Yy1</i>	absent egg cylinders	embryo phenotype
<i>Yy1</i>	pallor	integument phenotype
<i>Yy1</i>	neonatal lethality, complete penetrance	mortality/aging
<i>Yy1</i>	embryonic lethality, complete penetrance	mortality/aging
<i>lqcb1</i>	decreased total body fat amount	adipose tissue phenotype
<i>lqcb1</i>	decreased thigmotaxis	behavior/neurological phenotype
<i>lqcb1</i>	increased lean body mass	growth/size/body region phenotype

<i>lqcb1</i>	increased cornea thickness	vision/eye phenotype
<i>lqcb1</i>	no abnormal phenotype detected	normal phenotype
<i>lqcb1</i>	thick ventricular wall	cardiovascular system phenotype
<i>lqcb1</i>	preweaning lethality, incomplete penetrance	mortality/aging
<i>lqcb1</i>	increased heart left ventricle size	cardiovascular system phenotype
<i>Coro1a</i>	enlarged lymph nodes	immune system phenotype
<i>Coro1a</i>	decreased spleen weight	hematopoietic system phenotype,immune system phenotype
<i>Coro1a</i>	increased spleen weight	hematopoietic system phenotype,immune system phenotype,growth/size/body region phenotype
<i>Coro1a</i>	no abnormal phenotype detected	normal phenotype
<i>Coro1a</i>	abnormal T cell activation	hematopoietic system phenotype,immune system phenotype
<i>Coro1a</i>	abnormal T cell physiology	hematopoietic system phenotype,immune system phenotype
<i>Coro1a</i>	decreased susceptibility to bacterial infection	immune system phenotype
<i>Coro1a</i>	decreased susceptibility to systemic lupus erythematosus	immune system phenotype
<i>Coro1a</i>	abnormal thymocyte activation	hematopoietic system phenotype,immune system phenotype,endocrine/exocrine gland phenotype
<i>Coro1a</i>	decreased memory T cell number	hematopoietic system phenotype,immune system phenotype
<i>Coro1a</i>	increased mast cell degranulation	hematopoietic system phenotype,immune system phenotype,cellular phenotype
<i>Coro1a</i>	decreased thymocyte number	hematopoietic system phenotype,immune system phenotype,endocrine/exocrine gland phenotype
<i>Coro1a</i>	glomerulonephritis	immune system phenotype,renal/urinary system phenotype
<i>Coro1a</i>	decreased T cell number	hematopoietic system phenotype,immune system phenotype
<i>Coro1a</i>	increased thymocyte number	hematopoietic system phenotype,immune system phenotype,endocrine/exocrine gland phenotype
<i>Coro1a</i>	small lymph nodes	immune system phenotype
<i>Coro1a</i>	decreased autoantibody level	immune system phenotype
<i>Coro1a</i>	abnormal effector T cell morphology	hematopoietic system phenotype,immune system phenotype
<i>Coro1a</i>	decreased interleukin-6 secretion	immune system phenotype
<i>Coro1a</i>	increased T cell apoptosis	hematopoietic system phenotype,immune system phenotype,cellular phenotype
<i>Coro1a</i>	impaired macrophage phagocytosis	hematopoietic system phenotype,immune system phenotype,cellular phenotype
<i>Coro1a</i>	abnormal leukocyte migration	hematopoietic system phenotype,immune system phenotype,cellular phenotype
<i>Coro1a</i>	hyperactivity	behavior/neurological phenotype
<i>Coro1a</i>	decreased tumor necrosis factor secretion	immune system phenotype
<i>Coro1a</i>	increased susceptibility to systemic lupus erythematosus	immune system phenotype

<i>Coro1a</i>	decreased monocyte cell number	hematopoietic system phenotype,immune system phenotype
<i>Coro1a</i>	decreased B cell number	hematopoietic system phenotype,immune system phenotype
<i>Coro1a</i>	decreased T cell proliferation	hematopoietic system phenotype,immune system phenotype,cellular phenotype
<i>Coro1a</i>	enlarged spleen	hematopoietic system phenotype,immune system phenotype,growth/size/body region phenotype
<i>Coro1a</i>	decreased CD8-positive, alpha-beta T cell number	hematopoietic system phenotype,immune system phenotype
<i>Coro1a</i>	decreased interleukin-2 secretion	immune system phenotype
<i>Coro1a</i>	decreased CD4-positive, alpha-beta T cell number	hematopoietic system phenotype,immune system phenotype
<i>Cpsf4l</i>	increased circulating alanine transaminase level	homeostasis/metabolism phenotype
<i>Wdr19</i>	absent frontal bone	craniofacial phenotype,skeleton phenotype
<i>Wdr19</i>	abnormal spine curvature	skeleton phenotype
<i>Wdr19</i>	split sternum	skeleton phenotype
<i>Wdr19</i>	abnormal premaxilla morphology	craniofacial phenotype,skeleton phenotype
<i>Wdr19</i>	abnormal limb paddle morphology	limbs/digits/tail phenotype
<i>Wdr19</i>	abnormal maxilla morphology	craniofacial phenotype,skeleton phenotype
<i>Wdr19</i>	abnormal cilium morphology	cellular phenotype
<i>Wdr19</i>	abnormal craniofacial development	craniofacial phenotype
<i>Wdr19</i>	short face	craniofacial phenotype,growth/size/body region phenotype
<i>Wdr19</i>	abnormal tympanic ring morphology	hearing/vestibular/ear phenotype
<i>Wdr19</i>	interparietal bone hypoplasia	craniofacial phenotype,skeleton phenotype
<i>Wdr19</i>	cleft palate	craniofacial phenotype,digestive/alimentary phenotype,growth/size/body region phenotype
<i>Wdr19</i>	embryonic lethality during organogenesis, complete penetrance	mortality/aging
<i>Wdr19</i>	short ribs	skeleton phenotype
<i>Wdr19</i>	absent supraoccipital bone	craniofacial phenotype,skeleton phenotype
<i>Wdr19</i>	abnormal vertebrae morphology	skeleton phenotype
<i>Wdr19</i>	abnormal mandibular angle morphology	craniofacial phenotype,skeleton phenotype
<i>Wdr19</i>	polyphalangy	limbs/digits/tail phenotype,skeleton phenotype
<i>Wdr19</i>	short maxilla	craniofacial phenotype,skeleton phenotype
<i>Wdr19</i>	abnormal sternum ossification	skeleton phenotype
<i>Wdr19</i>	polydactyly	limbs/digits/tail phenotype
<i>Wdr19</i>	absent tibia	limbs/digits/tail phenotype,skeleton phenotype
<i>Wdr19</i>	abnormal limb mesenchyme morphology	embryo phenotype,limbs/digits/tail phenotype
<i>Wdr19</i>	abnormal limb development	limbs/digits/tail phenotype
<i>Wdr19</i>	anophthalmia	vision/eye phenotype
<i>Wdr19</i>	cleft secondary palate	craniofacial phenotype,digestive/alimentary phenotype,growth/size/body region phenotype

<i>Wdr19</i>	abnormal somite development	embryo phenotype
<i>Wdr19</i>	abnormal rib morphology	skeleton phenotype
<i>Wdr19</i>	lethality throughout fetal growth and development, complete penetrance	mortality/aging
<i>Wdr19</i>	rib bifurcation	skeleton phenotype
<i>Wdr19</i>	ectopic digits	limbs/digits/tail phenotype
<i>Wdr19</i>	abnormal dermomyotome development	muscle phenotype
<i>Wdr19</i>	parietal bone hypoplasia	craniofacial phenotype,skeleton phenotype
<i>Wdr19</i>	abnormal palatal shelf fusion at midline	craniofacial phenotype,digestive/alimentary phenotype,growth/size/body region phenotype
<i>Wdr19</i>	decreased palatine bone horizontal plate size	craniofacial phenotype,digestive/alimentary phenotype,growth/size/body region phenotype,skeleton phenotype
<i>Wdr19</i>	short mandible	craniofacial phenotype,skeleton phenotype
<i>Wdr19</i>	abnormal myotome development	muscle phenotype
<i>Wdr19</i>	abnormal cranium morphology	craniofacial phenotype,skeleton phenotype
<i>Wdr19</i>	exencephaly	nervous system phenotype
<i>Wdr19</i>	rib fusion	skeleton phenotype
<i>Wdr19</i>	abnormal palatine bone morphology	craniofacial phenotype,skeleton phenotype
<i>Wdr19</i>	bilateral cleft upper lip	craniofacial phenotype,growth/size/body region phenotype
<i>Wdr19</i>	short premaxilla	craniofacial phenotype,skeleton phenotype

**Supplementary Table 13. STRINGdb Analysis Results\***

Category	term ID	term description	background gene count	strength	false discovery rate	matching proteins in your network (labels)
GO Function	GO:0001601	Peptide YY receptor activity	3	2.91	0.0304	NPY1R,NPY5R
GO Function	GO:0001602	Pancreatic polypeptide receptor activity	4	2.79	0.0304	NPY1R,NPY5R
GO Function	GO:0030976	Thiamine pyrophosphate binding	8	2.49	0.0455	DHTKD1,TKTL2
UniProt Keywords	KW-0786	Thiamine pyrophosphate	13	2.28	0.0433	DHTKD1,TKTL2
SMART	SM00861	Transketolase, pyrimidine binding domain	7	2.55	0.0182	DHTKD1,TKTL2

\*Enriched terms for the protein-protein interaction network identified by STRINGdb when querying whole-genome sequence common variant analysis interaction gene loci (rs281851, rs13118183) reported in Table 1

**Supplementary Table 14. DGIdb Query Results**

Gene	Drug	Interaction Score	Interaction Types	Sources	PMIDs
<b>CAMK1D</b>	LOSARTAN	1.72		PharmGKB	25410890
<b>NPY1R</b>	CHEMBL1585652	2.58		DTC	
<b>NPY1R</b>	CHEMBL422942	2.58		TTD	
<b>NPY1R</b>	N6-PHENYLADENOSINE	1.1		DTC	
<b>NPY1R</b>	CHEMBL530291	1.1		DTC	
<b>NPY1R</b>	NEUROPEPTIDE-Y	3.86		TTD	
<b>NPY1R</b>	CHEMBL324554	7.73		DTC	
<b>NPY5R</b>	VELNEPERIT	30.91	antagonist	TdgClinicalTrial ChemblInteractions	
<b>NPY5R</b>	S-237648	15.46	antagonist	ChemblInteractions	
<b>NPY5R</b>	PEPTIDE YY HUMAN (3-36)	5.15		TdgClinicalTrial	
<b>NPY5R</b>	FR-79620	15.46		TTD	
<b>EYA2</b>	Solypertine Tartrate	1.03		DTC	
<b>EYA2</b>	(R)-Edelfosine	1.03		DTC	
<b>EYA2</b>	Hexamethyl Pararosaniline	1.03		DTC	

**Supplementary Table 15. QIAGEN Canonical Pathway Enrichment Analysis Results**

Genes	Pathway	P-Value
<i>PI4K2B, UBLCP1</i>	3-phosphoinositide Biosynthesis	<b>8.13E-03</b>
<i>PI4K2B, UBLCP1</i>	Superpathway of Inositol Phosphate Compounds	<b>1.05E-02</b>
<i>RAP1GAP</i>	Rap1 signalling	<b>1.05E-02</b>
<i>PI4K2B</i>	D-myo-inositol (1,4,5)-Trisphosphate Biosynthesis	<b>1.70E-02</b>
<i>YY1</i>	Transcriptional regulation by the AP-2 (TFAP2) family of transcription factors	<b>2.34E-02</b>
<i>RAP1GAP</i>	RET signaling	<b>2.69E-02</b>
<i>MED31, ZNF773</i>	Generic Transcription Pathway	<b>3.16E-02</b>
<i>SCUBE2</i>	Hedgehog ligand biogenesis	<b>4.17E-02</b>
<i>YY1</i>	VDR/RXR Activation	5.01E-02
<i>YY1</i>	Activation of anterior HOX genes in hindbrain during early embryogenesis	5.25E-02
<i>PI4K2B</i>	PI Metabolism	5.25E-02
<i>MED31</i>	Transcriptional regulation of white adipocyte differentiation	5.37E-02
<i>YY1</i>	ESR-mediated signaling	7.59E-02
<i>MED31</i>	Regulation of lipid metabolism by PPARalpha	7.59E-02
<i>RAP1GAP</i>	Endocannabinoid Developing Neuron Pathway	8.13E-02
<i>RAP1GAP</i>	Gai Signaling	8.91E-02